Two patients developed drug induced lupus secondary to sulfasalazine (
SSZ). One patient was receiving SSZ for Crohn's disease and was subseq
uently treated with olsalazine, which lacks the sulfapyridine componen
t of SSZ. Her inflammatory bowel disease (IBD) remained controlled and
she did not develop a recurrence of lupus, suggesting that olsalazine
is safe in patients with IBD and a history of SSZ induced lupus. The
SSZ induced antibodies were predominantly IgG against the (H2A-H2B)-DN
A complex. Since lupus induced by 7 other drugs was associated with a
similar antibody response, our findings support the existence of a com
mon pathway for autoantibody induction.